Alcami Corporation’s Post

In recent times, the biopharmaceutical sector has seen a surge in the development of oligonucleotides for human medicinal applications, spanning both therapeutic uses and vaccine formulations. This category includes a diverse array of entities such as small interfering RNAs (siRNA) and microRNA (miRNA), along with plasmid DNA (pDNA) and messenger RNA (mRNA) vaccines. Discover the intricacies involved in the analytical testing of oligonucleotide products and explore the varying degrees of assistance provided by William Boomershine, Ph.D. through his latest whitepaper titled, Navigating the Analytical Complexity of Oligonucleotide Therapeutics ➡️https://gag.gl/n2bMIO #labservices #askalcami #alcami #oligonucleotide #analytical #CDMO

In recent years, the biopharmaceutical sector has seen an expansive development of oligonucleotides as human medications, serving both therapeutic and vaccine purposes. This category includes a diverse array of products such as small interfering RNAs (siRNA) and microRNA (miRNA), plasmid DNA (pDNA), and messenger RNA (mRNA) vaccines. Discover the intricacies involved in the analytical testing of oligonucleotide products and the varying degrees of support provided by William Boomershine, Ph.D., in his latest whitepaper titled Navigating the Analytical Complexity of Oligonucleotide Therapeutics ➡️https://gag.gl/n2bMIO #labservices #askalcami #alcami #oligonucleotide #analytical #CDMO

View the Full Video: https://buff.ly/499fCs4 - Across Monoclonal antibodies (mAbs), Antibody-drug conjugates (ADCs), Peptide-drug conjugates (PDCs), Oligonucleotides, Large or small molecule biomarkers or metabolites, Proteins and Peptides. We partner with clients evolving new modalities in large molecule bioanalysis as a provider of R&D solutions for today’s most promising biopharmaceuticals and biologics. Leverage our expertise in the evaluation of pharmacokinetics, efficacy, and safety at competitive cost and timeline. #BioDuroSundia #LargeMolecule #Bioanalysis #Antibody #Antibodies #Monoclonal #mAb #AntibodyDrug #ADC #PeptideDrug #PDC, #Oligonucleotide #Biomarker #Metabolite #Protein #Peptide

In recent times, the biopharmaceutical sector has seen a surge in the development of oligonucleotides for human medicine, serving both therapeutic and vaccine purposes. These oligonucleotides vary greatly in size and type, including small interfering RNAs (siRNA) and microRNA (miRNA), plasmid DNA (pDNA), as well as messenger RNA (mRNA) vaccines. Discover more about the complexities involved in the analytical testing of oligonucleotide products and the varying degrees of assistance offered by William Boomershine, Ph.D. through his latest whitepaper titled, Navigating the Analytical Complexity of Oligonucleotide Therapeutics ➡️https://gag.gl/n2bMIO #labservices #askalcami #alcami #oligonucleotide #analytical #CDMO

Innovent Biologics VEGF blocker meets primary endpoint in ph02 neovascular age-related macular degeneration (nAMD) Chinese biotechnology company Innovent Biologics has reported that the Phase II clinical trial of efdamrofusp alfa high-dose (IBI302) in Chinese participants with neovascular age-related macular degeneration (nAMD) met its primary endpoint.IBI302 is a new recombinant human VEGFR-Fc-Human CR1 fusion protein injection that is intended to treat nAMD.The double-masked, randomised, active-controlled Phase II study assessed longer intervals between intravitreal injections of high-dose IBI302.It involved 132 patients who were randomised into three groups to receive 6.4mg of IBI302, 8mg of IBI302, or 2mg of Aflibercept, with dosing intervals adjusted based on post-loading therapy response.The primary endpoint was the variation in best corrected visual acuity (BCVA) in the trial eye from baseline to week 40.According to the findings, both IBI302 groups met the primary endpoint, demonstrating non-inferiority to the Aflibercept arm. https://lnkd.in/eYm_WquJ

#Primary_Cells Market Share Expected Huge Growth during 2023-2032 https://lnkd.in/dmXKXJke The rise in the prevalence of cancer cases will drive the growth of the primary cell #market. The increase in the #biopharmaceutical and #biotechnology sector for medical research is anticipated to foster the market expansion of the primary cell. Using patient-derived samples in advanced #preclinical #technologies, like #3D cell #cultures, which produce accurate results, boosts the market #growth of #primary #cells. Thermo Fisher Scientific Lonza Cell Biologics, Inc PromoCell ZenBio STEMCELL Technologies AllCells ATCC-American-Type-Culture-Collection Axol Bioscience Ltd. #Primary_Cells #healthcare #business_opportunities #marketanalysis #marketresearch #opportunities #business #future #primary #cells

Thoughts on this? >> Australian RNA manufacturer launches; Forge Biologics’ CEO steps down >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #healthcare #pharmaceutical #pharma #productmarketing

What challenges and advancements are involved in navigating the discovery and development of Bispecific Antibodies (bsAbs) in therapeutics? Join Kevin (Guangbo) Liu for the roundtable discussion at our Antibody Therapeutics Roundtable Xchange happening in San Diego, February 26th. To secure your spot, view full agendas and more, please visit https://lnkd.in/ew2y26Yv Please note: Registration is only open to Senior Scientists and above actively working in the #pharmaceutical / #biotech industry. Each roundtable is limited to 8 participants. #hubXchangeNotAConference #pharma #bigdata #datasciences #lifesciences #drugdevelopment #pharmacology #genomics #advancedtherapies #therapeutics #therapies #antibodytherapeutics #antibodyoptimisation #antibodydiscovery #emergingtechnologies #targetedtherapies

Don't miss William Boomershine, Ph.D., in his featured piece for The Medicine Maker, titled Navigating the Analytical Complexity of Oligonucleotide Therapeutics. Discover the entire article here ➡️ https://gag.gl/C1a3PT #Alcami #TheMedicineMaker #Oligonucleotides #biopharma #pharma #AskAlcami #CDMO #Tides #FillFinish

What challenges and advancements are involved in navigating the discovery and development of Bispecific Antibodies (bsAbs) in therapeutics? Join Kevin (Guangbo) Liu for the roundtable discussion at our Antibody Therapeutics Roundtable Xchange happening in San Diego, February 26th. To secure your spot, view full agendas and more, please visit https://lnkd.in/eUhXgMbZ Please note: Registration is only open to Senior Scientists and above actively working in the #pharmaceutical / #biotech industry. Each roundtable is limited to 8 participants. #hubXchangeNotAConference #pharma #bigdata #datasciences #lifesciences #drugdevelopment #pharmacology #genomics #advancedtherapies #therapeutics #therapies #antibodytherapeutics #antibodyoptimisation #antibodydiscovery #emergingtechnologies #targetedtherapies